School of Medicine

Wayne State University School of Medicine
K.V. Honn Cancer & Metastasis Research Group
Department of Pathology

Past Research Projects

Kenneth V. Honn, Principal Investigator
  1. Prostaglandins and Lysosomal Mediated Tumor Metastasis. WSU Research Development Fund. P.I., K.V. Honn, 6/1/79 to 5/31/80, $6,760.

  2. New Approach for the Control of Tumor Metastasis. The Milheim Foundation for Cancer Research. P.I., K.V. Honn, 7/1/80 to 6/30/81, $12,000.

  3. Evaluation of the Antimetastatic Effects of Bay g 6575. Miles Institute for Preclinical Pharmacology. P.I. , K.V. Honn, 6/1/80 to 5/31/81, $3,000.

  4. Studies on Prostacyclin and Tumor Metastasis. NIH/NCI, P.I., K.V. Honn, 10/1/80 to 9/30/83, $104,787.

  5. Studies on Thromboxane Synthetase Inhibitors and Cancer. Comprehensive Cancer Center of Metropolitan Detroit. P.I., K.V. Honn, 10/1/80 to 9/31/81, $10,000.

  6. Studies on Thromboxane Synthetase Inhibitors as Antimetastatic Agents. American Cancer Society. P.I., K.V. Honn, 1/1/81 to 12/31/82, $94,151.

  7. Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI. P.I., K.V. Honn, 4/1/81 to 3/31/84, $158,339.

  8. Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. P.I., K.V. Honn, 2/1/81 to 1/31/ 82, $59,000.

  9. Studies on the Antimetastatic Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. P.I., K.V. Honn, 2/1/81 to 1/31/82, $5, 060.

  10. Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. P.I., K.V. Honn, 2/1/82 to 1/31/83, $ 57,000.

  11. Cancer Chemoprevention and Arachidonate Metabolism. NIH/NCI. L.J. Marnett, K.V. Honn and B.F. Sloane, (P.I. L.J. Marnett), 8/1/82 to 7/31/85, $350,000.

  12. Evaluation of the Antitumor and/or Antimetastatic Activities of CGS-13080 and CGS-14854. Ciba-Geigy Corporation. P.I., K.V. Honn, 10/1/82 to 9/30/83, $14,460.

  13. Evaluation of Antitumor and Antimetastatic Activities of Thromboxane Synthetase Inhibitors. Pfizer Corporation. P.I., K.V. Honn, 10/1/82 to 9/30/83. $15,000.

  14. Development of Monoclonal Antibodies to Cathepsin B. Harper\Grace Hospitals. K.V. Honn and B.F. Sloane, (P.I., K.V. Honn), 7/1/83 to 8/31/84, $127,000.

  15. Studies on Prostacyclin and Tumor Metastasis. NIH/NCI CA29405. P.I., K.V. Honn, 7/7/83 to 12/31/86, $189,183.

  16. Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI CA36481. B.F. Sloane and K.V. Honn, (P.I.,B.F. Sloane), 12/1/83 to 11/30/86, $341,000.

  17. Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI CA29997. P.I.,K.V. Honn, 4/1/84 to 12/31/87, $341,113.

  18. Studies on Metastasis. Harper/Grace Hospitals. K.V. Honn, L.J. Marnett and B.F. Sloane, (P.I., K.V. Honn), 1/1/85 to 6\30\86, $160,000.

  19. Studies on Metastasis. Thomae Pharaceutical. K.V. Honn and L.J. Marnett (P.I., K.V. Honn), 1/1/85 to 12/31/85, $60,000.

  20. Studies on Metastasis. Harper-Grace Hospitals. K.V. Honn, L.J. Marnett, B.F. Sloane, C.J. Johnson and J.M. Onoda (P.I., K.V. Honn), 12/1/85 to 8/31/87, $175,000.

  21. Development of Lipoxygenase Inhibitors. Harper/Grace Hospitals. K.V. Honn, L. J. Marnett, C. Johnson (P.I. K. V. Honn), 9/1/87 to 6/30/89, $250,000 (direct costs).

  22. Role of Platelets in Hematogenous Metastasis. American Cancer Society. P.I., K.V. Honn, 1/1/86 to 12/31/87, $190,000.

  23. Role of Platelets in Hematogenous Metastasis. American Cancer Society. K.V. Honn (P.I. K.V. Honn) Interim Funding 1/1/88 to 6/30/89, $48,000.

  24. Studies on Radiporotection, Coagulation and Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 10/1/88 to 9/30/89, $100,297 (direct costs).

  25. Studies on Metastasis. Thomae Pharmaceutical. K.V. Honn and L.J. Marnett, (P.I., K.V. Honn), 1/1/87 to 12/31/90, $60,000 (direct costs).

  26. Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI, (P.I. K.V. Honn), 5/1/88 to 4/31/92, $418,323 (direct costs).

  27. Studies on 12-Lipoxygenase–Ono Pharmaceuticals. K.V. Honn, C.R. Johnson, and L.J. Marnett (P.I. K.V. Honn). 1/1/89 to 12/31/92, $2,525,000 (direct costs).

  28. Studies on Radiporotection, Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 1/1/90 to 12/31/93, $104,921 (direct costs).

  29. Supplemental Equipment Grant for Metastasis Program–Harper Grace Hospitals. J.M. Onoda and K.V. Honn (P.I. K.V. Honn), 5/1/91 to 9/30/94, $157,000 (direct costs).

  30. Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI Bonus Grant. B.F. Sloane and K.V. Honn, (P.I., B.F. Sloane), 7/1/87 to 6/30/93, $493,046 (direct costs).

  31. New Signal Transduction Pathways in Metastatic Melanoma Cells. NATO Linkage Grant (P.I. K.V. Honn) 1/1/93 to 12/31/95, $26,000 (direct costs).

  32. Signal Transduction in Tumor Metastasis. Fogarty International Research Collaboration Award. (P.I. K.V. Honn) 9/1/93 to 8/31/96, $60,000 (direct costs).

  33. Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis. Cancer Research Foundation of America (P.I.., K.V. Honn) 1/1/97 to 12/31/97, $25,000 (direct costs).

  34. Role of Signaling in the Progression of Melanoma. NATO Linkage Grant (P.I., K.V. Honn) 1/1/95 to 12/31/97, $26,000 (direct costs).

  35. Studies on Metastasis, Harper Hospital Development (P.I. K.V. Honn), 9/1/94 - 8/30/98, $248,000 (direct costs).

  36. Prognostic Markers for Prostate Cancer, Harper Hospital Development, (P.I. K.V. Honn) 9/1/94 to 6/30/98, $99,000 (direct costs).

  37. Metastatic Studies: Potential Involvement of Integrin beta in Tumor Progression and Metastasis). Harper Hospital Development, (P.I. K.V. Honn) 11/1/94 to 10/31/98, $100,000 (direct costs).

  38. Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI. CA#47115, (P.I. K.V. Honn), 03/01/95 to 02/28/99, $1,178,331 (direct and indirect costs).

  39. Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis. Cancer Research Foundation of America (P.I.., K.V. Honn) 04/15/97 to 04/15/99, $55,000 (direct costs).

  40. Studies on Metastasis. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $248,000 (direct costs).

  41. Prognostic Markers for Prostate Cancer. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $99,000 (direct costs).

  42. Bioactive Lipids: Role in Prostate Cancer Angiogenesis. DOD/Army (P.I., K.V. Honn) 9/30/98 to 3/30/01, $468,750 (direct and indirect costs).

  43. Arachidonate Acid 12-Lipoxygenase Inhibitors for Anti-Angiogenesis Therapy of Prostate Cancer. CAPCure (P.I. KV Honn), 01/01/99 to 12/31/01, $75,000.

  44. Role of Eicosanoids in Tumor Cell Metastasis. NIH/NCI. CA#29997, (P.I. K.V. Honn), 02/01/96 to 01/31/00, $988,291.

  45. Development Grant - PCa Progression and Metastasis, NIH/NCI. CA#69845 (P.I. K.V. Honn) 09/01/95 - 08/31/01, $1,028,820 (direct costs).

  46. Thromboxane Synthase as a Target for Anti-Angiogenesis Therapy of Prostate Cancer. Cancer Research Foundation of America. (P.I. K.V. Honn) 4/15/01-4/14/03, $60,000 (direct costs only).

  47. Thromboxane Synthase and Prostate Cancer Progression. DOD/Army (P.I. K.V. Honn), 7/15/01 - 10/14/05, $558,750 (direct & indirect costs).

  48. Formulation and Evaluation of a Prostate Cancer Drug, Phase 1. NIH/STTR Phase 1 (P.I. K.V. Honn), 9/1/02 - 2/28/06, $148,000

  49. Faculty Graduate Research Assistantship. Wayne State University (Mentor K.V. Honn), 8/15/05 - 8/14/06, $20,500 (direct costs).


Krishnarao Maddipati, Principal Investigator 

 Purification and Crystallization of Human 12-LOX Enzymes. NIH/STTR (P.I. K. Maddipati), 9/1/04 - 9/30/05, $99,864 

Dao-Tai Nie, Principal Investigator

Lipoxygenase, Angiogenicity, and Prostate Cancer Radioresistance. DOD/Army (P.I. D. Nie), 1/1/04 - 1/30/07, $336,017 (direct and indirect costs).

A Tissue Engineering Approach to Study the Progression of Breast Cancer Metastasis in Bone.  DOD/Army (P.I. D. Nie), 9/30/04 - 10/29/05, $112,725 (direct & indirect costs).